The purpose of this study is to demonstrate that primary prevention patients with one or more additional risk factors (1.5 prevention criteria: syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent pre-ventricular contractions (PVCs), and low left ventricular ejection fraction (LVEF)) are at a similar risk of life-threatening ventricular arrhythmias (LTVA) when compared to secondary prevention patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy- defibrillator (CRT-D) implant.
Devices allowed in the study include any Medtronic single, dual, or triple chamber defibrillator that has received appropriate license or regulatory approval and is commercially available by Medtronic in the geography in which the implant will take place. Any market-released, commercially available lead(s) can be used in the study.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
4,222
Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
Time to the First Occurrence of a Ventricular Arrhythmia
Time to the first occurrence of an episode of true ventricular tachycardia or fibrillation 24 Month rates will be provided for the two groups used in the primary endpoint definition. However, the primary endpoint of hazard ratio is presented in Statistical Analysis 1 as a ratio between Groups A and C.
Time frame: Hazard ratio from study enrollment to approximately 4 years post-implant/enrollment (as reported in Statistical Analysis 1), and estimated 24 month VT-VF rate (as compared in the Outcome Measure table between Groups A and C).
Mortality
Time to all-cause mortality
Time frame: Hazard ratio from study enrollment to approximately 4 years post-implant/enrollment (as reported in Statistical Analysis 1), and estimated 24 month mortality rate (as compared in the Outcome Measure table between Groups C and D).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Churruca
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Hospital Universitario Fundación Favaloro
Buenos Aires, Argentina
Instituto Cardiovascular de Buenos Aires (ICBA)
Buenos Aires, Argentina
Republican Scientific and Practical Center "Cardiology"
Minsk, Belarus
Real e Benemérita Associação Portuguesa de Beneficência
São Paulo, São Paulo, Brazil
INCOR - Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Brazil
INCOR - Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Brazil
Anhui Provincial Hospital
Hefei, Anhui, China
Xiamen Heart Center
Xiamen, Fujian, China
...and 83 more locations